Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Tirofiban Action Pathway (new)
Homo sapiens
Drug Action Pathway
Tirofiban is a platelet aggregation inhibitor, also known under the brand name Aggrastat, it is used to prevent thrombotic events from occurring in those who are high-risk. It is administered intravenously and acts as an antagonist of the platelet glycoprotein IIb/IIIa receptor, this receptor is responsible for platelet aggregation in order to form a thrombus, without this signal from the receptor it stops aggregation. This inhibition created by the drug will cease once the drug is no longer infused into the patient's bloodstream.
References
Tirofiban Pathway (new) References
Guo YZ, Zhao ZW, Li SM, Chen LL: Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI. Sci Rep. 2021 Aug 25;11(1):17144. doi: 10.1038/s41598-021-96606-y.
Pubmed: 34433885
Juwana YB, Suryapranata H, Ottervanger JP, van 't Hof AW: Tirofiban for myocardial infarction. Expert Opin Pharmacother. 2010 Apr;11(5):861-6. doi: 10.1517/14656561003690005.
Pubmed: 20210689
McClellan KJ, Goa KL: Tirofiban. A review of its use in acute coronary syndromes. Drugs. 1998 Dec;56(6):1067-80. doi: 10.2165/00003495-199856060-00017.
Pubmed: 9878994
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings